Phase 1 N=40 MW151-101: First-in-human Study of MW151
Drug Toxicity
Primary: Percentage of Participants Experiencing Drug-related Serious Adverse Events. — 0; 0; 0; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 Delineation of Sensorimotor Subtypes Underlying Residual Speech Errors
Speech Sound Disorder
Primary: Normalized F3-F2 Distance, an Acoustic Measure That Correlates With Perceptual Accuracy of /r/, Measured From /r/ Sounds Produced in Treatment Sessions. — 5.73; 6.27…
Phase 1 N=180 W-SUDs for COVID-19
Substance Use Disorders · Alcohol Use Disorder
Primary: Change in Number of Substance Use Occasions in the Past 30 Days From Baseline to Post-treatment at 8 Weeks — -9.1; -4.7 occasions
Phase 1 N=32 Phase I Trial of 225Ac-J591 in Patients With mCRPC
Prostate Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 1 N=24 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Breast Atypical Ductal Hyperplasia · Breast Atypical Lobular Hyperplasia · Breast Ductal Carcinoma In Situ
Primary: Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities) — 0; 1; 1; 0 Participants
Phase 1 N=114 A Trial of Habit Formation Theory for Exercise in Older Adults
Sedentary Behavior · Aging · Activity, Motor
Primary: Change in Automaticity Score. — 17 Participants
Phase 1 N=7 A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants
Phase 1 N=24 CuidaTXT: a Text Message Dementia-caregiver Intervention for Latinos
Caregiver Burnout
Primary: Percentage of Participants Able to Opt Into CuidaTXT (Enrollment Feasibility) — 24 Participants
Phase 1 N=82 Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity
Cardiovascular Risk Factor
Primary: Change in Moderate (or Higher) Physical Activity Duration Following Message Receipt — 0.16; 0.13; 0.25; 0.31 minutes — p=0.037
Phase 1 N=120 Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
Phase 1 N=42 A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 0 Participants
Phase 1 N=9 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Recurrent Bladder Carcinoma · Stage 0a Bladder Urothelial Carcinoma · Stage 0is Bladder Urothelial Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab
Phase 1 N=18 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
HER2 Positive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer
Primary: Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Dose-limiting toxicities (DLTs)
Phase 1 N=44 A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Neoplasm Metastasis
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine — 2890; 2950 nanograms per milliliter (ng/mL)
Phase 1 N=31 Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
Asthma
Primary: Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge — -20.645; -16.949; -19.366; -12.064 percent change…